Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013.
Remes K, Anttila P, Silvennoinen R, Putkonen M, Ollikainen H, Terävä V, Sinisalo M, Kananen K, Schain F, Castren-Kortegangas P, Järvinen TM, Pisini M, Wahl F, Dixon T, Leval A. Remes K, et al. Among authors: anttila p. PLoS One. 2018 Dec 5;13(12):e0208507. doi: 10.1371/journal.pone.0208507. eCollection 2018. PLoS One. 2018. PMID: 30517181 Free PMC article.
Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT.
Grövdal M, Nahi H, Gahrton G, Liwing J, Waage A, Abildgaard N, Pedersen PT, Hammerstrøm J, Laaksonen A, Bazia P, Terava V, Ollikainen H, Silvennoinen R, Putkonen M, Anttila P, Porkka K, Remes K. Grövdal M, et al. Among authors: anttila p. Bone Marrow Transplant. 2015 Jun;50(6):808-12. doi: 10.1038/bmt.2015.39. Epub 2015 Apr 13. Bone Marrow Transplant. 2015. PMID: 25867654 Clinical Trial.
A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.
Silvennoinen R, Anttila P, Säily M, Lundan T, Heiskanen J, Siitonen TM, Kakko S, Putkonen M, Ollikainen H, Terävä V, Kutila A, Launonen K, Räsänen A, Sikiö A, Suominen M, Bazia P, Kananen K, Selander T, Kuittinen T, Remes K, Jantunen E. Silvennoinen R, et al. Among authors: anttila p. Bone Marrow Transplant. 2016 Mar;51(3):372-6. doi: 10.1038/bmt.2015.236. Epub 2015 Oct 5. Bone Marrow Transplant. 2016. PMID: 26437056 Free PMC article. Clinical Trial.
Cost analysis of a randomized stem cell mobilization study in multiple myeloma.
Varmavuo V, Silvennoinen R, Anttila P, Säily M, Sankelo M, Putkonen M, Ahonen J, Mahlamäki E, Mäntymaa P, Savolainen ER, Remes K, Jantunen E. Varmavuo V, et al. Among authors: anttila p. Ann Hematol. 2016 Oct;95(10):1653-9. doi: 10.1007/s00277-016-2772-1. Epub 2016 Aug 3. Ann Hematol. 2016. PMID: 27485453 Clinical Trial.
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group.
Luoma S, Anttila P, Säily M, Lundan T, Heiskanen J, Siitonen T, Kakko S, Putkonen M, Ollikainen H, Terävä V, Sankelo M, Partanen A, Launonen K, Räsänen A, Sikiö A, Suominen M, Bazia P, Kananen K, Lievonen J, Selander T, Pelliniemi TT, Ilveskero S, Huotari V, Mäntymaa P, Tienhaara A, Jantunen E, Silvennoinen R. Luoma S, et al. Among authors: anttila p. Ann Hematol. 2019 Dec;98(12):2781-2792. doi: 10.1007/s00277-019-03815-7. Epub 2019 Oct 31. Ann Hematol. 2019. PMID: 31673775 Free PMC article. Clinical Trial.
Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma.
Silvennoinen R, Lundan T, Kairisto V, Pelliniemi TT, Putkonen M, Anttila P, Huotari V, Mäntymaa P, Siitonen S, Uotila L, Penttilä TL, Juvonen V, Selander T, Remes K. Silvennoinen R, et al. Among authors: anttila p. Blood Cancer J. 2014 Oct 10;4(10):e250. doi: 10.1038/bcj.2014.69. Blood Cancer J. 2014. PMID: 25303369 Free PMC article. Clinical Trial.
Prognostic significance of esterase gene expression in multiple myeloma.
Kumari R, Majumder MM, Lievonen J, Silvennoinen R, Anttila P, Nupponen NN, Lehmann F, Heckman CA. Kumari R, et al. Among authors: anttila p. Br J Cancer. 2021 Apr;124(8):1428-1436. doi: 10.1038/s41416-020-01237-1. Epub 2021 Feb 3. Br J Cancer. 2021. PMID: 33531688 Free PMC article.
Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients.
Silvennoinen R, Kairisto V, Pelliniemi TT, Putkonen M, Anttila P, Säily M, Sikiö A, Opas J, Penttilä K, Kuittinen T, Honkanen T, Lundán T, Juvonen V, Luukkaala T, Remes K. Silvennoinen R, et al. Among authors: anttila p. Br J Haematol. 2013 Feb;160(4):561-4. doi: 10.1111/bjh.12139. Epub 2012 Dec 4. Br J Haematol. 2013. PMID: 23206270 Free article. Clinical Trial. No abstract available.
Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing.
Majumder MM, Silvennoinen R, Anttila P, Tamborero D, Eldfors S, Yadav B, Karjalainen R, Kuusanmäki H, Lievonen J, Parsons A, Suvela M, Jantunen E, Porkka K, Heckman CA. Majumder MM, et al. Among authors: anttila p. Oncotarget. 2017 May 5;8(34):56338-56350. doi: 10.18632/oncotarget.17630. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915594 Free PMC article.
141 results